Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the health-check domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /dom76025/wp-includes/functions.php on line 6121
Health Canada Approves Galderma's Restylane SHAYPE for Chin Augmentation - The Dermatology Digest
Search

Health Canada Approves Galderma’s Restylane SHAYPE for Chin Augmentation

Health Canada has given its nod to Restylane SHAYPE, a hyaluronic acid (HA) injectable designed for temporary augmentation of the chin region.

Galderma Restylane SHAYPE will be available in Canada as of February 2024. Other regulatory reviews around the world are ongoing, the Company reports.

Powered by new NASHA HD technology from Galderma, Restylane SHAYPE has the highest G’ (“G prime”) of the Restylane product range.

“Restylane SHAYPE is the next generation in HA, going beyond currently available options for chin augmentation,” says Baldo Scassellati Sforzolini, MD, PhD, the Global Head of R & D at Galderma, in a news release. “Developed with leading experts, this innovative breakthrough has a unique ability to create the strength and support needed for a bone-mimicking effect. This makes Restylane®SHAYPE an ideal choice for lower face shaping, offering durable, natural-looking results for up to 12 months without retreatment.” 

In a pivotal 12-month study conducted at nine sites across Canada, 91% of patients agreed they still had aesthetic improvements at 12 months, and 84% of patients would agree to be treated with Restylane SHAYPE again. Furthermore, up to 97% of patients would recommend treatment with Restylane SHAYPE to a friend and 95% of patients felt their results looked natural.

“A product with a significant ability to create a bone-mimicking effect without the downtime of surgery has long been an unmet need, highlighted by the community of plastic surgeons, dermatologists, and aesthetic injectors all over the world,” adds Andreas Nikolis, MD, MSc, FRCSC Dr. Andreas Nikolis is an Associate Professor of Plastic Surgery at the Université de Montreal’s Division of Plastic Surgery and Senior Medical Director of Victoria Park Medispa in Montreal, Canada,

“The development of the ideal gel required a significant increase in firmness to create the strength and support needed to shape the lower face. Now, through meticulous clinical evaluation, Galderma has achieved the development of a safe and effective HA injectable for chin remodeling.”